Aug 8 (Reuters) - Eli Lilly (NYSE:LLY) and Co LLY.N :
* LILLY ANNOUNCES POSITIVE RESULTS FOR EMGALITY™ (GALCANEZUMAB) FROM THE CONQUER STUDY IN PATIENTS WHO FAILED PREVIOUS MIGRAINE PREVENTIVE TREATMENTS
* ELI LILLY AND CO - STUDY MET PRIMARY AND ALL KEY SECONDARY OUTCOMES IN CONQUER